Designing Longevity
Skip to main content
Strong EvidencePeptide

Semaglutide

The Ozempic molecule

GLP-1 Receptor Agonist

Last updated: October 2026
Share:

is a synthetic version of , a hormone your body naturally makes after eating. It tells your brain you're full and slows digestion. Originally developed for type 2 diabetes, it turned out to be remarkably effective for weight loss, so effective that it launched the current GLP-1 revolution.

Evidence Level: Strong Evidence

Multiple large human trials, FDA approval, established safety profile

Regulatory Status: FDA-approved for diabetes (Ozempic), weight loss (Wegovy), and noncirrhotic MASH with moderate-to-advanced liver fibrosis (Wegovy)

How It Works

mimics the hormone that your gut releases when you eat. But while natural GLP-1 lasts only minutes, semaglutide stays active for about a week (that's why it's a weekly injection).

It works through several mechanisms:
• Brain: Reduces appetite and food cravings at the source
• Stomach: Slows emptying so you feel full longer
• Pancreas: Improves insulin release and blood sugar control
• Liver: Reduces glucose production

The net effect: you naturally eat less without the constant battle against hunger that sabotages traditional diets.

Evidence by Outcome

Each claim below is rated using a GRADE-aligned five-tier system. Same molecule, different outcomes, different evidence.

Evidence at a glance

How we grade

Want to see how this compares to every other peptide? Browse the full evidence matrix, where every graded claim is grouped by outcome and sorted by certainty.

Weight lossHigh certainty

Produces ~15% mean body-weight loss over 68 weeks at 2.4mg/week in adults with obesity.

Population: Adults with BMI ≥30, or ≥27 with at least one weight-related comorbidity, without type 2 diabetes

Why this rating

Direct evidence from large, well-designed RCTs: STEP 1 (n=1,961; −14.9% vs −2.4% at 68 weeks) and STEP 5 (n=304; −15.2% vs −2.6% at 104 weeks). STEP 12 adds an independent phase 3b replication in Chinese adults with overweight or obesity (n=242; −12.1% vs −2.2% at 44 weeks), supporting the effect across populations and trial settings. No serious GRADE downgrade factors apply.

Supporting studies

Reviewed October 2026· Designing Longevity EditorialHow we grade
Cardiovascular outcomesHigh certainty

Reduces major adverse cardiovascular events (CV death, nonfatal MI, nonfatal stroke) by ~20% in adults with overweight/obesity and pre-existing cardiovascular disease.

Population: Adults with BMI ≥27 and pre-existing cardiovascular disease, without type 2 diabetes

Why this rating

Single very large pre-registered RCT (SELECT, n=17,604) with a hard composite endpoint, mean follow-up 39.8 months, HR 0.80 (95% CI 0.72–0.90). Confidence intervals are tight (no imprecision) and the population is directly relevant. Pending replication; the trial has not yet been independently reproduced, which prevents an unqualified statement of certainty.

GRADE downgrade factors applied

  • Inconsistency: Heterogeneous results across studies that cannot be explained, or pending replication.

Supporting studies

Reviewed October 2026· Designing Longevity EditorialHow we grade
Muscle preservationLow certainty

May contribute to loss; structured resistance training and adequate protein are commonly recommended to mitigate this.

Population: Adults losing weight on semaglutide

Why this rating

Body-composition substudies of RCTs (including STEP 1 DXA substudy) report that ~25–40% of total weight lost is , a proportion broadly consistent with non-pharmacologic weight loss but still material. Evidence for specific mitigation strategies (protein intake, resistance training) in GLP-1 users is largely indirect, extrapolated from non-GLP-1 weight-loss research. Direct RCTs comparing with-vs-without resistance training in users are limited.

GRADE downgrade factors applied

  • Indirectness: Studied population, intervention, comparator, or outcome differs from the question being answered.
  • Imprecision: Wide confidence intervals or small sample size, the estimate could be substantially different.

Supporting studies

Reviewed October 2026· Designing Longevity EditorialHow we grade
Kidney outcomesHigh certainty

Reduces the risk of major kidney-disease progression events (kidney failure, a 50% or greater fall in eGFR, or death from kidney or cardiovascular causes) by about 24% in adults with type 2 diabetes and chronic kidney disease.

Population: Adults with type 2 diabetes and chronic kidney disease (reduced eGFR with elevated albuminuria)

Why this rating

One large, pre-registered, RCT (FLOW, n=3,533) that was stopped early for efficacy. The primary composite of kidney failure, a sustained 50% or greater reduction in eGFR, or death from kidney or cardiovascular causes occurred less often on 1.0mg than placebo (HR 0.76, 95% CI 0.66–0.88, p=0.0003), a clinically meaningful 24% relative risk reduction with a precise confidence interval and a hard, patient-relevant endpoint. The single downgrade reflects that this pivotal trial has not yet been independently replicated. Note the population is type 2 diabetes with chronic kidney disease, not the obesity-without-diabetes population of the weight-loss claim.

GRADE downgrade factors applied

  • Inconsistency: Heterogeneous results across studies that cannot be explained, or pending replication.

Supporting studies

Reviewed October 2026· Designing Longevity EditorialHow we grade
Liver outcomesModerate certainty

Improves liver histology in MASH: at 72 weeks about 63% of patients had resolution of steatohepatitis without worsening fibrosis and about 37% had fibrosis improvement without worsening steatohepatitis, versus roughly 34% and 22% on placebo.

Population: Adults with biopsy-proven metabolic dysfunction-associated steatohepatitis (MASH) and moderate-to-advanced fibrosis (stage 2 or 3)

Why this rating

One large, multicenter, double-blind, RCT (ESSENCE, primary analysis n=800) showed 2.4mg beat placebo on both histologic at 72 weeks: resolution of steatohepatitis without worsening of fibrosis (62.9% vs 34.3%) and fibrosis improvement without worsening of steatohepatitis (36.8% vs 22.4%), both p<0.001. Downgraded for indirectness because the endpoints are liver-biopsy surrogates rather than long-term clinical outcomes (progression to cirrhosis, liver failure, or death), and this is the interim primary analysis of a single trial with longer-term outcome data still to come. The result supported the FDA's 2025 of semaglutide () for noncirrhotic MASH with moderate-to-advanced fibrosis.

GRADE downgrade factors applied

  • Indirectness: Studied population, intervention, comparator, or outcome differs from the question being answered.

Supporting studies

Reviewed October 2026· Designing Longevity EditorialHow we grade

Potential Benefits

  • STEP 1: mean 14.9% weight loss at 68 weeks with weekly 2.4 mg, versus 2.4% with placebo, in the studied adults without diabetes.
  • Significantly reduced appetite and food cravings
  • Improved blood sugar control and insulin sensitivity
  • Cardiovascular benefits (reduced heart attack and stroke risk in some populations)
  • Weekly injection and daily tablet options have different instructions.
  • Substantial human trial and prescribing experience, with important product-specific risks.

Risks & Considerations

  • GI side effects are common (nausea, vomiting, diarrhea, constipation), usually improve over time
  • Weight loss can include lean tissue as well as fat; nutrition and activity need an individualized plan.
  • Rare risk of (severe abdominal pain = call doctor immediately)
  • The label contraindicates use with personal or family medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2.
  • May cause gallbladder problems in some users
  • The full cost depends on the exact medicine, dose, insurance, manufacturer self-pay or savings eligibility, and any separate . A list price is not necessarily the amount you will pay. Compare the current program costs and manufacturer-direct options, then confirm the amount due and renewal terms before enrolling.
  • Local stock and coverage can change; national shortage history does not establish current availability.

Dosing Information

comes in different products and forms. includes weekly injections, a 7.2 mg Wegovy HD injection for eligible adults, and daily tablets. Indications, starting doses, missed-dose instructions and storage depend on the exact product. A dose or rule for cannot automatically be applied to Wegovy.

  • •The dose schedule depends on the indication and exact medicine. Use the prescription and current instructions supplied with it.
  • •Milligrams and handling rules are not interchangeable between an injection, a tablet, a preparation and different brand devices.

Need to mix this from a vial?

Use our reconstitution calculator to get the exact insulin syringe units to draw.

Want to know what this actually costs?

Compare monthly costs across our vetted provider cohort, with trust caveats up front.

Practical Tips

  • 1Follow the instructions for your exact product. For a single missed injection, the label uses the time until the next scheduled dose, with a 48-hour threshold; missed Wegovy tablets are skipped. Several missed injections may require a different restart plan. Ask your pharmacist if unsure; do not use a universal five-day rule for all products.
  • 2Storage and discard rules differ by product and device. Check the carton instructions and ask the dispensing pharmacist before using a medicine exposed to the wrong temperature.
  • 3Tell the prescriber about side effects, other medicines and planned procedures before changing treatment.

Key Research

Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)

New England Journal of Medicine, 2021

At 68 weeks, mean body-weight change was −14.9% with vs −2.4% with placebo (n=1,961). 86.4% of semaglutide participants lost ≥5% body weight vs 31.5% with placebo.

View Study

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT)

New England Journal of Medicine, 2023

Among 17,604 adults with overweight/obesity and pre-existing CVD but no diabetes, reduced the composite of CV death, nonfatal MI, or nonfatal stroke (6.5% vs 8.0%; HR 0.80, 95% CI 0.72–0.90; p<0.001) over a mean follow-up of 39.8 months.

View Study

Two-year effects of semaglutide in adults with overweight or obesity (STEP 5)

Nature Medicine, 2022

At 104 weeks, mean body-weight change was −15.2% with vs −2.6% with placebo (n=304). 77.1% of semaglutide participants achieved ≥5% weight loss vs 34.4% with placebo, with weight loss sustained over two years.

View Study

Sources behind this update

Editorial check: 2026-10-15. Updated product forms, handling, direct-comparison and cost guidance. Other outcome ratings retain their individual review dates.

Compare current costs and manufacturer payment routes

Compare weight-management options

Learn how the medicines differ, then review eligibility and coverage with a clinician or plan.

Compare GLP-1 providersInsurance helpCompare with tirzepatide

For medical decisions, discuss established options with a licensed clinician.

Frequently Asked Questions

Are compounded versions approved generics?

drugs are not FDA-approved. FDA does not review them for safety, effectiveness or quality before they are marketed, and a pharmacy license or accreditation does not establish equivalence to an approved medicine. FDA recommends compounded drugs only when an FDA-approved drug cannot meet a patient's medical needs. Discuss the specific product with a licensed prescriber and pharmacist; this directory does not establish that it is safe for you.

Can every pharmacy compound this medicine?

Not automatically. A prescription and a pharmacy license alone do not establish compliance. FDA's April 1, 2026 policy update says and are on neither its shortage list nor the bulks list. Section restricts routine compounding of essentially copies of commercially available drugs; a prescriber-documented change that makes a significant difference for an individual patient is one relevant exception. Check current FDA guidance and discuss the specific prescription with a licensed prescriber and pharmacist.

How much does semaglutide cost?

The full cost depends on the exact medicine, dose, insurance, manufacturer self-pay or savings eligibility, and any separate . A list price is not necessarily the amount you will pay. Compare the current program costs and manufacturer-direct options, then confirm the amount due and renewal terms before enrolling.

How much weight can I realistically lose on semaglutide?

In STEP 1, adults with overweight or obesity without diabetes assigned weekly 2.4 mg plus lifestyle support lost a mean 14.9% of body weight at 68 weeks, versus 2.4% with placebo. This is a trial average for that dose and population, not a promise or a result for every semaglutide product.

How long does it take for semaglutide to start working?

Appetite and weight changes vary. Dose escalation is designed around the exact product and tolerability, not a guaranteed deadline for results. Follow the prescribed schedule rather than increasing the dose to chase a result.

What are the most common semaglutide side effects?

Stomach and bowel symptoms such as nausea, vomiting, diarrhea and constipation are common. Rates and warnings depend on the exact product and population; some symptoms are serious or persistent. Read its prescribing information and ask the prescriber about symptoms rather than waiting for a promised adjustment period.

Can I drink alcohol while taking semaglutide?

We cannot label alcohol use safe for everyone taking . Discuss drinking with the prescriber, particularly if you have diabetes, use medicines that can cause low blood sugar or have a history of . Ask about your full medication list.

What happens if I miss a dose of semaglutide?

Follow the instructions for your exact product. For a single missed injection, the label uses the time until the next scheduled dose, with a 48-hour threshold; missed Wegovy tablets are skipped. Several missed injections may require a different restart plan. Ask your pharmacist if unsure; do not use a universal five-day rule for all products.

Is semaglutide the same as Ozempic?

comes in different products and forms. includes weekly injections, a 7.2 mg Wegovy HD injection for eligible adults, and daily tablets. Indications, starting doses, missed-dose instructions and storage depend on the exact product. A dose or rule for cannot automatically be applied to Wegovy.

Will I regain weight if I stop taking semaglutide?

Weight regain was observed after withdrawal in clinical research, including the STEP 1 extension. That does not predict an individual result or mean everyone needs the same duration of treatment. Discuss an ongoing weight-management plan before stopping.

How do I minimize muscle loss on semaglutide?

Ask your clinician or dietitian about adequate nutrition and resistance exercise for your health and ability. is not the same as muscle alone, and body-composition study percentages do not tell you how much muscle you personally will lose. This guide does not prescribe a universal protein or supplement dose.

Where to source this

See full directory

Editorial inclusion only, no financial relationship with these providers. See our vetting methodology.

Eden

Vertically-integrated GLP-1 telehealth with notable customer-service caveats

Dated profile recordChecked May 1, 2026
Compounded GLP-1

Eden has the most ambitious supply-chain story in our cohort, they own the pharmacy that fills your prescription, with a publicized per-lot testing program. The catch is the gap between the marketing and the operational record. We list Eden because the structural advantages are real, but we score the experience-side dimensions honestly.

Full profile last checked May 1, 2026. Program terms may have separate check dates.

$39 first month, then $99/month; medication extra.

No financial relationship
View profile
Compounded GLP-1

Ro

A branded-prescription membership with medication coverage navigation.

Program termsChecked October 13, 2026
Brand-name GLP-1

Ro is worth comparing when insurance paperwork is the main friction. It publishes a coverage-support pathway and multiple billing terms; the care fee remains payable even when the drug uses insurance.

Program checked October 13, 2026. Earlier public record checked May 1, 2026.

$149 / month care fee; medication separate

No financial relationship
View profile
Brand-name GLP-1

Hims & Hers

A separate care membership around a branded prescription.

Program termsChecked October 13, 2026
Brand-name GLP-1

Hims publishes a cash-pay membership with medication billed separately. Compare the care fee, prescribed product and pharmacy bill before enrolling.

Program checked October 13, 2026. Earlier public record checked May 1, 2026.

$149 / month care fee; medication separate

No financial relationship
View profile
Brand-name GLP-1

New to Peptides?

Learn the basics of peptide therapy, how to inject safely, and what to look for in quality sources.

What Are Peptides? Peptide Safety Guide

Related Goals

The Weight Loss GuideThe Slow Aging Guide

Compare Semaglutide

Semaglutide vs Tirzepatide

The direct evidence, its limits and the questions that change the decision

Related Peptides

TirzepatideDual GLP-1/GIP Receptor Agonist

Disclaimer: This information is for educational purposes only and is not medical advice. Many peptides discussed are not FDA-approved for human use. Always consult with a qualified healthcare provider before starting any treatment. Evidence levels and regulatory status can change, this content was last updated October 2026.

Found this helpful? Share it or save it for later.

Share: